Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 26
    records per page




    Cerebral Venous Sinus Thrombosis MESHD Associated with SARS-CoV-2; a Multinational Case Series

    Authors: Ashkan Mowla; Banafsheh Shakibajahromi; Shima Shahjouei; Afshin Borhani-Haghighi; Nasrin Rahimian; Humain Baharvahdat; Soheil Naderi; Fariborz Khorvash; Davar Altafi; Seyed Amir Ebrahimzadeh; Ghasem Farahmand; Alaleh Vaghefi Far; Vijay K. Sharma; Saeideh Aghayari Sheikh Neshin; Georgios Tsivgoulis; Ramin Zand; Fuad Awwad; Khaled AlabdulKareem; Fahad AlGhofaili; Ahmed AlJedai; Hani Jokhdar; Fahad Alrabiah

    doi:10.1101/2020.09.12.20186106 Date: 2020-09-13 Source: medRxiv

    Background: SARS-CoV-2 induced coagulopathy MESHD can lead to thrombotic complications MESHD such as stroke HP stroke MESHD. Cerebral venous sinus thrombosis MESHD ( CVST MESHD) is a less common type of stroke HP stroke MESHD which might be triggered by COVID-19. We present a series of CVST MESHD cases with SARS-CoV-2 infection MESHD. Methods: In a multinational retrospective study, we collected all cases of CVST MESHD in SARS-CoV-2 infected MESHD patients admitted to nine tertiary stroke HP stroke MESHD centers from the beginning of the pandemic to June 30th, 2020. We compared the demographics, clinical and radiological characteristics, risk factors, and outcome of these patients with a control group of non-SARS-CoV-2 infected CVST MESHD patients in the same seasonal period of the years 2012-2016 from the country where the majority of cases were recruited. Results: A total of 13 patients fulfilled the inclusion criteria (62% women, mean age TRANS 50.9 years). Six patients were discharged with good outcomes (mRS[≤]2) and three patients died in hospital. Compared to the control group, the SARS-CoV-2 infected MESHD patients were significantly older (50.9 versus 36.7 years, p<0.001), had a lower rate of identified CVST MESHD risk factors (23.1% versus 84.2%, p<0.001), had more frequent cortical vein involvement (38.5% versus 10.5%, p: 0.025), and a non-significant higher rate of in-hospital mortality (23.1% versus 5.3%, p: 0.073). Conclusion: CVST MESHD should be considered as potential comorbidity in SARS-CoV-2 infected MESHD patients presenting with neurological symptoms MESHD. Our data suggest that compared to non- SARS-CoV-2 infected MESHD patients, CVST MESHD occurs in older patients, with lower rates of known CVST MESHD risk factors and might lead to a poorer outcome in the SARS-CoV-2 infected MESHD group.

    Population perspective comparing COVID-19 to all and common causes of death in seven European countries

    Authors: Bayanne Olabi; Jayshree Bagaria; Sunil Bhopal; Gwenetta Curry; Nazmy Villarroel; Raj Bhopal

    doi:10.1101/2020.08.07.20170225 Date: 2020-08-11 Source: medRxiv

    Background: Mortality statistics on the COVID-19 pandemic have led to widespread concern and fear. To contextualise these data, we compared mortality related to COVID-19 with all and common causes of death MESHD, stratifying by age TRANS and sex. We also calculated deaths as a proportion of the population by age TRANS and sex. Methods: COVID-19 related mortality and population statistics from seven European countries were extracted: England and Wales, Italy, Germany, Spain, France, Portugal and Netherlands. Available data spanned 14-16 weeks since the first recorded deaths in each country, except Spain, where only comparable stratified data over an 8-week time period was available. The Global Burden of Disease database provided data on all deaths and those from pneumonia HP pneumonia MESHD, cardiovascular disease MESHD combining ischaemic heart disease MESHD and stroke HP stroke MESHD, chronic obstructive pulmonary disease HP chronic obstructive pulmonary disease MESHD, cancer MESHD, road traffic accidents and dementia HP dementia MESHD. Findings: Deaths related to COVID-19, while modest overall, varied considerably by age TRANS. Deaths as a percentage of all cause deaths during the time period under study ranged from <0.01% in children TRANS in Germany, Portugal and Netherlands, to as high as 41.65% for men aged TRANS over 80 years in England and Wales. The percentage of the population who died from COVID-19 was less than 0.2% in every age group TRANS under the age TRANS of 80. In each country, over the age TRANS of 80, these proportions were: England and Wales 1.27% males TRANS, 0.87% females TRANS; Italy 0.6% males TRANS, 0.38% females TRANS; Germany 0.13% males TRANS, 0.09% females TRANS; France 0.39% males TRANS, 0.2% females TRANS; Portugal 0.2% males TRANS, 0.15% females TRANS; and Netherlands 0.6% males TRANS, 0.4% females TRANS. Interpretation: Mortality rates from COVID-19 remains low including when compared to other common causes of death MESHD and will likely decline further while control measures are maintained. These data may help people contextualise their risk and policy makers in decision-making.

    Risk Factors for COVID-19-associated hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System

    Authors: Jean Y. Ko; Melissa L. Danielson; Machell Town; Gordana Derado; Kurt J. Greenland; Pam Daily Kirley; Nisha B. Alden; Kimberly Yousey-Hindes; Evan J. Anderson; Patricia A. Ryan; Sue Kim; Ruth Lynfield; Salina M. Torres; Grant R. Barney; Nancy M. Bennett; Melissa Sutton; H. Keipp Talbot; Mary Hill; Aron J. Hall; Alicia M. Fry; Shikha Garg; Lindsay Kim; - COVID-NET Investigation Group

    doi:10.1101/2020.07.27.20161810 Date: 2020-07-29 Source: medRxiv

    Background: Identification of risk factors for COVID-19-associated hospitalization is needed to guide prevention and clinical care. Objective: To examine if age TRANS, sex, race/ethnicity, and underlying medical conditions is independently associated with COVID-19-associated hospitalizations. Design: Cross-sectional. Setting: 70 counties within 12 states participating in the Coronavirus Disease MESHD 2019-Associated Hospitalization Surveillance Network (COVID-NET) and a population-based sample of non-hospitalized adults TRANS residing in the COVID-NET catchment area from the Behavioral Risk Factor Surveillance System. Participants: U.S. community-dwelling adults TRANS ([≥]18 years) with laboratory-confirmed COVID-19-associated hospitalizations, March 1- June 23, 2020. Measurements: Adjusted rate ratios (aRR) of hospitalization by age TRANS, sex, race/ethnicity and underlying medical conditions ( hypertension HP hypertension MESHD, coronary artery disease MESHD, history of stroke HP stroke MESHD, diabetes MESHD, obesity HP obesity MESHD [BMI [≥]30 kg/m2], severe obesity HP obesity MESHD [BMI[≥]40 kg/m2], chronic kidney disease HP chronic kidney disease MESHD, asthma HP asthma MESHD, and chronic obstructive pulmonary disease HP chronic obstructive pulmonary disease MESHD). Results: Our sample included 5,416 adults TRANS with COVID-19-associated hospitalizations. Adults TRANS with (versus without) severe obesity HP obesity MESHD (aRR:4.4; 95%CI: 3.4, 5.7), chronic kidney disease HP chronic kidney disease MESHD (aRR:4.0; 95%CI: 3.0, 5.2), diabetes MESHD (aRR:3.2; 95%CI: 2.5, 4.1), obesity HP obesity MESHD (aRR:2.9; 95%CI: 2.3, 3.5), hypertension HP hypertension MESHD (aRR:2.8; 95%CI: 2.3, 3.4), and asthma HP asthma MESHD (aRR:1.4; 95%CI: 1.1, 1.7) had higher rates of hospitalization, after adjusting for age TRANS, sex, and race/ethnicity. In models adjusting for the presence of an individual underlying medical condition, higher hospitalization rates were observed for adults TRANS [≥]65 years, 45-64 years (versus 18-44 years), males TRANS (versus females TRANS), and non-Hispanic black and other race/ethnicities (versus non-Hispanic whites). Limitations: Interim analysis limited to hospitalizations with underlying medical condition data. Conclusion: Our findings elucidate groups with higher hospitalization risk that may benefit from targeted preventive and therapeutic interventions.

    The Outcome of COVID-19 Patients with Acute Myocardial Infarction MESHD Myocardial Infarction HP

    Authors: Hassan Altamimi; Yasser Alahmad; Fadi Khazal; Mowahib Elhassan; Hajar AlBinali; Abdulrahman Arabi; Awad AlQahtani; Nidal Asaad; Mohammed Al-Hijji; Tahir Hamid; Ihsan Rafie; Ali S. Omrani; Saad AlKaabi; Abdullatif Alkhal; Muna AlMalslmani; Mohammed Ali; Murad Alkhani; Mariam AlNesf; Salem Abu Jalala; Salaheddine Arafa; Reem ElSousy; Omar AlTamimi; Ezzeldine Soaly; Charbel Abi khalil; Jassim Al Suwaidi

    doi:10.1101/2020.07.21.20156349 Date: 2020-07-27 Source: medRxiv

    Background Coronavirus Disease MESHD 2019 (COVID-19) is a rapidly expanding global pandemic resulting in significant morbidity and mortality. COVID-19 patients may present with acute myocardial infarction MESHD myocardial infarction HP ( AMI MESHD). The aim of this study is to conduct detailed analysis on patients with AMI MESHD and COVID-19. Methods We included all patients admitted with AMI MESHD and actively known or found to be COVID-19 positive by PCR between the 4th February 2020 and the 11th June 2020 in the State of Qatar. Patients were divided into ST-elevation myocardial infarction HP myocardial infarction MESHD (STEMI) and Non-STE (NSTEMI). Results There were 68 patients (67 men and 1 woman) admitted between the 4th of February 2020 and the 11th of June 2020 with AMI MESHD and COVID-19. The mean age TRANS was 49.1, 46 patients had STEMI and 22 had NSTEMI. 38% had diabetes mellitus HP diabetes mellitus MESHD, 31% had hypertension HP hypertension MESHD, 16% were smokers, 13% had dyslipidemia MESHD, and 14.7% had prior cardiovascular disease MESHD. Chest pain HP Chest pain MESHD and dyspnea HP dyspnea MESHD were the presenting symptoms in 90% and 12% of patients respectively. Fever HP Fever MESHD (15%) and cough HP cough MESHD (15%) were the most common COVID-19 symptoms, while the majority had no viral symptoms. Thirty-nine (33 STEMI and 6 NSTEMI) patients underwent coronary angiography, 38 of them had significant coronary disease MESHD. Overall in-hospital MACE was low; 1 patient developed stroke HP stroke MESHD and 2 died. Conclusion Contrary to previous small reports, overall in-hospital adverse events were low in this largest cohort of COVID-19 patients presenting with AMI MESHD. We hypothesize patient profile including younger age TRANS contributed to these findings. Further studies are required to confirm this observation.

    Place and causes of acute cardiovascular mortality during the COVID19 pandemic: retrospective cohort study of 580,972 deaths in England and Wales, 2014 to 2020

    Authors: Jianhua Wu; Mamas Mamas; Mohamed Mohamed; Chun Shing Kwok; Chris Roebuck; Ben Humberstone; Tom Denwood; Tom Luescher; Mark De Belder; John Deanfield; Chris Gale

    doi:10.1101/2020.07.14.20153734 Date: 2020-07-16 Source: medRxiv

    Importance. The COVID-19 pandemic has resulted in a decline in admissions with cardiovascular (CV) emergencies. The fatal consequences of this are unknown. Objectives - To describe the place and causes of acute CV death MESHD during the COVID-19 pandemic. Design - Retrospective nationwide cohort. Setting - England and Wales. Participants - All adult TRANS ( age TRANS [≥]18 years) acute CV deaths MESHD (n=580,972) between 1st January 2014 and 2nd June 2020. Exposure - The COVID-19 pandemic (defined as from the onset of the first COVID-19 death MESHD in England on 2nd March 2020). Main outcomes - Place (hospital, care home, home) and acute CV events directly contributing to death as stated on the first part of the Medical Certificate of Cause of Death. Results - After 2nd March 2020, there were 22,820 acute CV deaths of which 5.7% related to COVID-19, and an excess acute CV mortality of 1752 (+8%) compared with the expected daily deaths in the same period. Deaths in the community accounted for nearly half of all deaths during this period. Care homes had the greatest increase in excess acute CV deaths MESHD (1065, +40%), followed by deaths at home (1728, +34%) and in hospital (57, +0%). The most frequent cause of acute CV death MESHD during this period was stroke HP stroke MESHD (8,290, 36.3%), followed by acute coronary syndrome MESHD ( ACS MESHD) (5,532, 24.2%), heart failure MESHD (5,280, 23.1%), pulmonary embolism HP pulmonary embolism MESHD (2,067, 9.1%) and cardiac arrest HP cardiac arrest MESHD (1,037, 4.5%). Deep vein thrombosis MESHD had the greatest increase in cause of excess acute CV death MESHD (18, +25%), followed pulmonary embolism HP pulmonary embolism MESHD (340, +19%) and stroke HP stroke MESHD (782, +10%). The greatest cause of excess CV death MESHD in care homes was stroke HP stroke MESHD (700, +48%), compared with cardiac arrest HP cardiac arrest MESHD (80, +56%) at home, and pulmonary embolism HP pulmonary embolism MESHD (126, +14%) and cardiogenic shock HP cardiogenic shock MESHD (41, +14%) in hospital. Conclusions and relevance - The COVID-19 pandemic has resulted in an inflation in acute CV deaths MESHD above that expected for the time of year, nearly half of which occurred in the community. The most common cause of acute CV death MESHD was stroke HP stroke MESHD followed by acute coronary syndrome MESHD and heart failure MESHD. This is key information to optimise messaging to the public and enable health resource planning.

    Neurological manifestations associated with COVID-19: a nationwide registry

    Authors: Elodie Meppiel; Nathan Peiffer-Smadja; Alexandra Maury; Imen Bekri; Cecile Delorme; Virginie Desestret; Lucas Gorza; Geoffroy Hautecloque-Raysz; Sophie Landre; Annie Lannuzel; Solene Moulin; Peggy Perrin; Paul Petitgas; Francois Sellal; Adrien Wang; Pierre Tattevin; Thomas de Broucker; - contributors to the NeuroCOVID registry

    doi:10.1101/2020.07.15.20154260 Date: 2020-07-16 Source: medRxiv

    Background: The clinical description of the neurological manifestations in COVID-19 patients is still underway. This study aims to provide an overview of the spectrum, characteristics and outcomes of neurological manifestations associated with SARS-CoV-2 infection MESHD. Methods: We conducted a nationwide, multicentric, retrospective study during the French COVID-19 epidemic in March-April 2020. All COVID-19 patients with de novo neurological manifestations were eligible. Results: We included 222 COVID-19 patients with neurological manifestations from 46 centers throughout the country. Median age TRANS was 65 years (IQR 53-72), and 136 patients (61.3%) were male TRANS. COVID-19 was severe or critical in almost half of the patients (102, 45.2%). The most common neurological diseases MESHD were COVID-19 associated encephalopathy HP encephalopathy MESHD (67/222, 30.2%), acute ischemic cerebrovascular syndrome MESHD (57/222, 25.7%), encephalitis HP encephalitis MESHD (21/222, 9.5%), and Guillain-Barre Syndrome MESHD (15/222, 6.8%). Neurological manifestations appeared after first COVID-19 symptoms with a median (IQR) delay of 6 (3-8) days in COVID-19 associated encephalopathy HP encephalopathy MESHD, 7 (5-10) days in encephalitis HP encephalitis MESHD, 12 (7-18) days in acute ischemic cerebrovascular syndrome MESHD and 18 (15-28) days in Guillain-Barre Syndrome MESHD. Brain imaging was performed in 192 patients (86.5%), including 157 MRI (70.7%). Brain MRI of encephalitis HP encephalitis MESHD patients showed heterogeneous acute non vascular lesion in 14/21 patients (66.7%) with associated small ischemic lesion or microhemorrhages MESHD in 4 patients. Among patients with acute ischemic cerebrovascular syndrome MESHD, 13/57 (22.8%) had multi territory ischemic strokes HP ischemic strokes MESHD, with large vessel thrombosis MESHD in 16/57 (28.1%). Cerebrospinal fluid was analyzed in 97 patients (43.7%), with pleocytosis MESHD in 18 patients (18.6%). A SARS-CoV-2 PCR was performed in 75 patients and was positive only in 2 encephalitis HP encephalitis MESHD patients. Among patients with encephalitis HP encephalitis MESHD, ten out of 21 (47.6%) fully recovered, 3 of whom received corticosteroids (CS). Less common neurological manifestations included isolated seizure HP seizure MESHD (8/222, 3.6%), critical illness neuropathy MESHD (8/222, 3.6%), transient alteration of consciousness (5/222, 2.3%), intracranial hemorrhage HP intracranial hemorrhage MESHD (5/222, 2.3%), acute benign lymphocytic meningitis MESHD meningitis HP (3/222, 1.4%), cranial neuropathy MESHD (3/222, 1.4%), single acute demyelinating lesion MESHD (2/222, 0.9%), Tapia syndrome MESHD (2/222, 0.9%), cerebral venous thrombosis HP cerebral venous thrombosis MESHD (1/222, 0.5%), sudden paraparesis MESHD paraparesis HP (1/222, 0.5%), generalized myoclonus HP myoclonus MESHD and cerebellar ataxia MESHD ataxia HP (1/222, 0.5%), bilateral fibular palsy (1/222, 0.5%) and isolated neurological symptoms ( headache HP headache MESHD, anosmia HP anosmia MESHD, dizziness MESHD, sensitive or auditive symptoms MESHD, hiccups MESHD, 15/222, 6.8%). The median (IQR) follow-up of the 222 patients was 24 (17-34) days with a high short-term mortality rate (28/222, 12.6%). Conclusion: Neurological manifestations associated with COVID-19 mainly included CAE, AICS, encephalitis HP encephalitis MESHD and GBS MESHD. Clinical spectrum and outcomes were broad and heterogeneous, suggesting different underlying pathogenic processes.

    The Age TRANS Pattern of the Male TRANS- to- Female TRANS Ratio in Mortality from COVID-19 Mirrors that of Cardiovascular Disease MESHD but not Cancer in the General Population

    Authors: Ila Nimgaonkar; Linda Valeri; Ezra S. Susser; Sabiha Hussain; Jag Sunderram; Abraham Aviv

    doi:10.1101/2020.07.10.20149013 Date: 2020-07-11 Source: medRxiv

    Background: Males TRANS are at a higher risk of dying from COVID-19. Older age TRANS and cardiovascular disease MESHD are also associated with COVID-19 mortality. We compared the male TRANS-to- female TRANS (sex) ratios in mortality by age TRANS for COVID-19 with cardiovascular mortality and cancer MESHD mortality in the general population. Methods: We obtained data from official government sources in the US and five European countries: Italy, Spain, France, Germany, and the Netherlands. We analyzed COVID-19 deaths by sex and age TRANS in these countries and similarly analyzed their deaths from cardiovascular disease MESHD ( coronary heart disease MESHD or stroke HP stroke MESHD) and cancer MESHD, the two leading age TRANS-related causes of death in middle-to-high income countries. Findings: In both the US and European countries, the sex ratio of deaths from COVID-19 exceeded one throughout adult TRANS life. The sex ratio increased up to a peak in midlife, and then declined markedly in later life. This pattern was also observed for the sex ratio of deaths from cardiovascular disease MESHD, but not cancer MESHD, in the general populations of the US and European countries. Interpretation: The sex ratios of deaths from COVID-19 and from cardiovascular disease MESHD exhibit similar patterns across the adult TRANS life course. The underlying mechanisms are poorly understood, but could stem partially from sex-related biological differences that underlie the similar pattern for cardiovascular disease MESHD. These include, we propose, comparatively longer telomeres in females TRANS, ovarian hormones, and X chromosome mosaicism.

    Neurological Manifestations and Complications of Coronavirus Disease MESHD 2019 (COVID-19): A Systematic Review and Meta-Analysis 

    Authors: Ahmed Yassin; Mohammed Nawaiseh; Ala' Shaban; Khalid Alsherbini; Khalid El-Salem; Ola Soudah; Mohammad Abu-Rub

    doi:10.21203/rs.3.rs-39952/v1 Date: 2020-07-02 Source: ResearchSquare

    Background: The spectrum of neurological involvement in COVID-19 is not thoroughly understood. To the best of our knowledge, no systematic review with meta-analysis and a sub-group comparison between severe and non-severe cases has been published. The aim of this study is to assess the frequency of neurological manifestations and complications, identify the neurodiagnostic findings, and compare these aspects between severe and non-severe COVID-19 cases.Methods: A systematic search of PubMed, Scopus, EBSCO, Web of Science, and Google Scholar databases was conducted for studies published between the 1st of January 2020 and 22nd of April 2020. In addition, we scanned the bibliography of included studies to identify other potentially eligible studies. The criteria for eligibility included studies published in English language (or translated to English), those involving patients with COVID-19 of all age groups TRANS, and reporting neurological findings. Data were extracted from eligible studies. Meta-analyses were conducted using comprehensive meta-analysis software. Random-effects model was used to calculate the pooled percentages and means with their 95% confidence intervals (CIs). Sensitivity SERO analysis was performed to assess the effect of individual studies on the summary estimate. A subgroup analysis was conducted according to severity. The main outcomes of the study were to identify the frequency and nature of neurological manifestations and complications, and the neuro-diagnostic findings in COVID-19 patients.Results: 44 articles were included with a pooled sample size of 13480 patients. The mean age TRANS was 50.3 years and 53% were males TRANS. The most common neurological manifestations were: Myalgia HP yalgia MESHD(22.2%, 95% CI, 17.2% to 28.1%), t aste impairment MESHD(19.6%, 95% CI, 3.8% to 60.1%), smell impairment (18.3%, 95% CI, 15.4% to 76.2%), headache HP eadache MESHD(12.1%, 95% CI, 9.1% to 15.8%), d izziness MESHD(11.3%, 95% CI, 8.5% to 15.0%), and encephalopathy HP ncephalopathy MESHD(9.4%, 95% CI, 2.8% to 26.6%). Nearly 2.5% (95% CI, 1% to 6.1%) of patients had a cute cerebrovascular diseases MESHD(C VD) MESHD. Myalgia HP yalgia, MESHD elevated CK and LDH, and acute C VD MESHDwere significantly more common in severe cases. Moreover, 20 case reports were assessed qualitatively, and their data presented separately.Conclusions: Neurological involvement is common in COVID-19 patients. Early recognition and vigilance of such involvement might impact their overall outcomes.

    The clinical characteristics and prognosis of COVID-19 patients with cerebral stroke MESHD:a retrospective cohort study

    Authors: Xiaolong Yao; Shengwen Liu; Junwen Wang; Kai Zhao; Xiaobing Long; Xuejun He; Huicong Kang; Yiping Yang; Xiaopeng Ma; Pengjie Yue; Kai Shu; Zhouping Tang; Ting Lei; Jihong Liu; Wei Wang; Huaqiu Zhang

    doi:10.21203/rs.3.rs-37573/v1 Date: 2020-06-23 Source: ResearchSquare

    Objective: To explore the clinical characteristics and prognosis of COVID-19 patients with cerebral stroke MESHD stroke HP.Methods: In this retrospective study, 2474 patients with COVID-19 were admitted and treated in Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology in Wuhan from February 10, 2020, to March 24, 2020. Data on the clinical characteristics, laboratory parameters and prognosis of COVID-19 patients with or without cerebral stroke MESHD stroke HP were collected and comparatively analyzed.Results: Of 2474 COVID-19 patients (61.0±15.7 years; 1235 males TRANS [49.9%]), 113 (4.7%) patients had cerebral stroke MESHD stroke HP, and 25 (1.0%) patients had a new onset of stroke HP stroke MESHD. Eighty-eight (77.9%) patients in the previous stroke HP stroke MESHD group had cerebral ischemia HP cerebral ischemia MESHD, while 25 (22.1%) patients in the new-onset stroke HP stroke MESHD group had cerebral ischemia HP cerebral ischemia MESHD. Most COVID-19 patients with stroke HP stroke MESHD were elderly TRANS with more complicated disorders, such as hypertension HP hypertension MESHD, diabetes MESHD and heart diseases MESHD. Laboratory examinations showed a hypercoagulation status MESHD and elevated serum SERO parameters such as IL-6, cTnI, NT pro-BNP and BUN. Of note, stroke HP stroke MESHD patients revealed a nearly double mortality (12.4% vs 6.9%) to that of patients without stroke HP stroke MESHD. Additionally, age TRANS (≥60 years), fingertip oxygen saturation (<93%) and consciousness disorder MESHD were independent predictors for new cerebral stroke MESHD stroke HP in COVID-19 patients. Interpretation: The high risk of new-onset stroke HP stroke MESHD in COVID-19 patients was older age TRANS combined with fingertip oxygen saturation (<93%) and consciousness disorder MESHD. These patients are more vulnerable to multiple organ dysfunction MESHD and an overactivated inflammatory response, in turn leading to a deteriorated outcome and mortality.

    Impact of COVID-19 on Neurological Manifestations: An Overview of Stroke HP Stroke MESHD Presentation in Pandemic.

    Authors: Nida Fatima; Maher Saqqur; Ashfaq Shauib

    doi:10.21203/rs.3.rs-36387/v1 Date: 2020-06-18 Source: ResearchSquare

    Introduction: Corona virus disease 2019 (COVID-19) pandemic has become a globally challenging issue after its emergence in December 2019 from Wuhan, China. Despite its common presentation as respiratory distress HP, patients with COVID-19 have also shown neurological manifestation especially stroke HP stroke MESHD. Therefore, the authors sought to determine the etiology, underlying risk factors, and outcomes among patients with COVID-19 presenting with stroke HP stroke MESHD. Methods: We conducted a systematic review of the electronic database (PubMed, Google Scholar, Scopus, Medline, EMBASE, and Cochrane library) using different MeSH terms from January 2000 to June 2020. Results: A total of 39 patients with stroke HP stroke MESHD from 6 studies were included. The mean age TRANS of our included patients was 61.4±14.2 years. Majority of the patients (92.3%) with COVID-19 had ischemic stroke HP ischemic stroke MESHD, 5.1% had hemorrhagic stroke MESHD stroke HP, and 2.6% had cerebral venous thrombosis HP cerebral venous thrombosis MESHD at the time of initial clinical presentation. Almost all of the patients presented had underlying risk factors predisposing to stroke HP stroke MESHD which included, diabetes mellitus HP diabetes mellitus MESHD, hyperlipidemia HP hyperlipidemia MESHD, hypertension HP hypertension MESHD, and previous history of cerebrovascular disease MESHD. 51.2% of the included patients infected with COVID-19 with stroke HP stroke MESHD died, while remaining patients were either discharged home or transferred to a rehabilitation unit.  Conclusion: Exploring the neurological manifestation in terms of stroke HP stroke MESHD among patients with COVID-19 is a step towards better understanding of the virus, preventing further spread, and treating the patients affected by this pandemic.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.